RxDoctor Payments Data

Sonya Reid, MD

Hematology & Oncology · Nashville, TNNPI 1457795239

Payments from drug & device makers

$221,071in general payments, 2019–2025

Across 126 payments — averaging $1754.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$138K
  • Novartis$26K
  • Pfizer$21K
  • Gilead$19K
  • Daiichi Sankyo Inc.$10K
  • Eli Lilly$5K
  • plus $2K from 4 others
$32,957in research payments, 2019–2025

Across 5 payments — averaging $6591.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$32K
  • Novartis$665

What the payments were for

  • Consulting fees$95,55587%
  • Speaking & faculty fees$1,0771%
  • Grants$3500%
  • Travel & lodging$9,2288%
  • Food & beverage$3,9574%
  • Education$430%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$221,071 in reported general payments places this provider in the 70th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$29,280
Medicare patients
96
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib26$399,551
KisqaliRibociclib Succinate24$375,012
VerzenioAbemaciclib18$209,823
XareltoRivaroxaban13$11,131
Exemestane22$7,782
Letrozole122$2,825
Tamoxifen Citrate41$1,040
Ondansetron Hcl12$646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$21,372$399,55126 claims
NovartisKisqali$25,820$375,01224 claims
Lilly USA, LLCVerzenio$79$209,82318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 251 hematology & oncology providers in Tennessee.

Other hematology & oncology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →